NCT07779538
Clinical Trials Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Maintenance Therapy for Epithelial Ovarian Cancer
StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Recruitment opened
- Eligibility criteria expanded, about 16 words
- Start date changed from estimate of Sep 1, 2026 to Oct 20, 2026
- Site details revised at 3 of 3 sites
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Dose limited toxicity (DLT)
Timeframe: up to 21 days
Progression Free Survival (PFS)
Timeframe: the first 108 weeks, every 12 weeks, then every 24 weeks, lasting about 3 years
Secondary (11)
AEs+SAEs
Ctrough
ADA
Overall survival (OS)
Second progression-free survival (PFS2)
Show 6 moreShow less
Objective Response Rate (ORR)
Disease Control Rate (DCR)
Duration of Response (DoR)
Time to disease progression (TTP)
Cancer antigen-125 response rate (CA-125 RR)
Time to the start of subsequent treatment (TFST)
Arms and interventions
Treatment group AExperimental
Treatment group BOther
Drugs: trastuzumab, bevacizumab
Sites
3 sites in 1 country